C. Tyrrell

2.0k total citations
49 papers, 1.5k citations indexed

About

C. Tyrrell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, C. Tyrrell has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 10 papers in Genetics. Recurrent topics in C. Tyrrell's work include Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Estrogen and related hormone effects (10 papers). C. Tyrrell is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Estrogen and related hormone effects (10 papers). C. Tyrrell collaborates with scholars based in United Kingdom, Denmark and United States. C. Tyrrell's co-authors include Peter Iversen, Teuvo L.J. Tammela, Kevin Carroll, Amir V. Kaisary, John Anderson, M. C. Chamberlain, Hendrik Van Poppel, William A. See, I. Melezínek and Michael Peckham and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

C. Tyrrell

49 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Tyrrell United Kingdom 18 1.0k 415 322 303 277 49 1.5k
Kevin Carroll United Kingdom 13 942 0.9× 369 0.9× 288 0.9× 100 0.3× 241 0.9× 32 1.4k
D.W.W. Newling Netherlands 20 895 0.9× 279 0.7× 246 0.8× 75 0.2× 161 0.6× 43 1.3k
S.-O. Andersson Sweden 10 794 0.8× 463 1.1× 390 1.2× 125 0.4× 414 1.5× 12 1.5k
Geert J.C.M. Kolvenbag United States 19 1.3k 1.2× 653 1.6× 232 0.7× 342 1.1× 295 1.1× 35 1.6k
Anthony L. Patterson United States 23 1.2k 1.2× 333 0.8× 213 0.7× 89 0.3× 200 0.7× 44 1.6k
Joseph T. Spaulding United States 14 1.5k 1.5× 421 1.0× 459 1.4× 160 0.5× 259 0.9× 21 2.3k
Anton J. Bueschen United States 19 1.1k 1.1× 202 0.5× 302 0.9× 79 0.3× 179 0.6× 49 1.8k
Yasuhide Miyoshi Japan 24 1.0k 1.0× 306 0.7× 593 1.8× 126 0.4× 281 1.0× 137 2.0k
Paul Toren Canada 19 681 0.7× 219 0.5× 228 0.7× 120 0.4× 272 1.0× 77 1.2k
Mindaugas Jievaltas Lithuania 14 1.0k 1.0× 174 0.4× 217 0.7× 89 0.3× 304 1.1× 65 1.3k

Countries citing papers authored by C. Tyrrell

Since Specialization
Citations

This map shows the geographic impact of C. Tyrrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Tyrrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Tyrrell more than expected).

Fields of papers citing papers by C. Tyrrell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Tyrrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Tyrrell. The network helps show where C. Tyrrell may publish in the future.

Co-authorship network of co-authors of C. Tyrrell

This figure shows the co-authorship network connecting the top 25 collaborators of C. Tyrrell. A scholar is included among the top collaborators of C. Tyrrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Tyrrell. C. Tyrrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
See, William A., et al.. (2006). The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of Cancer Research and Clinical Oncology. 132(S1). 7–16. 53 indexed citations
2.
Wirth, Manfred P., C. Tyrrell, K.P.J. Delaere, et al.. (2006). Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer and Prostatic Diseases. 10(1). 87–93. 22 indexed citations
3.
Tyrrell, C., William A. See, David G. McLeod, et al.. (2005). Bicalutamide (‘Casodex’) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme. Radiotherapy and Oncology. 76(1). 4–10. 50 indexed citations
4.
Iversen, Peter, Manfred P. Wirth, William A. See, et al.. (2004). Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology. 63(5). 928–933. 12 indexed citations
5.
Tyrrell, C.. (1999). Adjuvant and Neoadjuvant Hormonal Therapy for Prostate Cancer. European Urology. 36(6). 549–558. 15 indexed citations
6.
Tyrrell, C., L. Denis, D.W.W. Newling, et al.. (1998). Casodex<sup>TM</sup> 10&ndash;200&nbsp;mg Daily, Used as Monotherapy for the Treatment of Patients with Advanced Prostate Cancer. European Urology. 33(1). 39–53. 48 indexed citations
7.
Debruyne, F., Robin Murray, Yves Fradet, et al.. (1998). Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology. 52(1). 72–81. 42 indexed citations
8.
9.
Jonat, W., Anthony Howell, Carl Blomqvist, et al.. (1996). A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *. European Journal of Cancer. 32(3). 404–412. 207 indexed citations
10.
Williams, C J, V. Barley, G. Blackledge, et al.. (1995). Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clinical Oncology. 7(2). 87–92. 9 indexed citations
11.
Tyrrell, C., P.F. Bruning, F May-Levin, et al.. (1994). Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. Research Explorer (The University of Manchester). 13 indexed citations
12.
Sewell, GJ, et al.. (1994). Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. Journal of Clinical Pharmacy and Therapeutics. 19(2). 127–133. 3 indexed citations
13.
Tyrrell, C.. (1994). Tolerability and Quality of LifeAspects with the Anti-AndrogenCasodex (IC1176,334) asMonotherapy for Prostate Cancer. European Urology. 26(1). 15–19. 17 indexed citations
14.
Callaway, Mark, et al.. (1994). Chemotherapy induced myocardial fibrosis. Clinical Oncology. 6(1). 55–56. 2 indexed citations
15.
Tyrrell, C., J. E. Altwein, Eberhard Varenhorst, et al.. (1993). Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. Cancer. 72(S12). 3878–3879. 23 indexed citations
16.
Tyrrell, C.. (1992). Casodex: A pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer. The Prostate. 21(S4). 97–104. 20 indexed citations
17.
Daniel, F., et al.. (1991). A pilot study of stanozolol for advanced breast carcinoma. Cancer. 67(12). 2966–2968. 7 indexed citations
18.
Daniel, F., Paul Macleod, & C. Tyrrell. (1990). Megestrol Acetate in Relapsed Carcinoma of Prostate. British Journal of Urology. 65(3). 275–277. 10 indexed citations
19.
Tyrrell, C., et al.. (1989). Acinic cell carcinoma—Plymouth's experience with postoperative radical radiotherapy. British Journal of Oral and Maxillofacial Surgery. 27(3). 186–191. 8 indexed citations
20.
Tyrrell, C., et al.. (1988). Stage 1 Hodgkin's disease of the nasopharynx. The Journal of Laryngology & Otology. 102(12). 1179–1181. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin Carroll Breakdown of academic impact, for papers by D.W.W. Newling Breakdown of academic impact, for papers by S.-O. Andersson Breakdown of academic impact, for papers by Geert J.C.M. Kolvenbag Breakdown of academic impact, for papers by Anthony L. Patterson Breakdown of academic impact, for papers by Joseph T. Spaulding Breakdown of academic impact, for papers by Anton J. Bueschen Breakdown of academic impact, for papers by Yasuhide Miyoshi Breakdown of academic impact, for papers by Paul Toren Breakdown of academic impact, for papers by Mindaugas Jievaltas
Rankless by CCL
2026